dr. o’shaughnessy on eribulin as first-line therapy for metastatic her2-negative breast cancer
Published 10 years ago • 297 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:11
joyce o’shaughnessy, md: candidacy for eribulin therapy
-
2:08
dr. joyce o'shaughnessy on eribulin in metastatic breast cancer
-
2:42
eribulin as treatment for metastatic breast cancer
-
1:11
joyce o’shaughnessy, md: candidacy for eribulin therapy
-
1:23
joyce o’shaughnessy, md: different mechanisms of action in eribulin
-
1:17
dr. mcintyre on a phase ii study analyzing first-line eribulin mesylate
-
0:53
joyce o’shaughnessy, md: principle third-line options for patients with metastatic tnbc
-
25:14
metastatic her2 negative breast cancer: emerging novel treatment strategies
-
0:59
joyce o’shaughnessy, md: main indications for dose reduction with eribulin
-
1:39
joyce o’shaughnessy, md: efficacy data supporting the use of eribulin mesylate
-
1:56
joyce o’shaughnessy, md: treatment goals for patients with tnbc and multiple metastatic sites
-
5:25
eribulin in metastatic breast cancer
-
2:19
dr. twelves discusses eribulin for the treatment of breast cancer
-
9:49
patient selection for eribulin in breast cancer
-
2:04
dr. joyce o’shaughnessy on promising agents in triple-negative breast cancer
-
1:40
dr. o'shaughnessy on the future of breast cancer biomarkers
-
1:58
dr. twelves on a pooled analysis of eribulin in breast cancer
-
1:20
joyce o’shaughnessy, md: fourth-line considerations
-
5:06
factors in deciding treatment for hr breast cancer